{"analyses":[{"ciLowerLimit":"0.46","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.87","estimateComment":"Reference level = placebo arm","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.002","paramType":"Hazard Ratio (HR)","paramValue":"0.63","statisticalComment":"One-sided test","statisticalMethod":"Gray's test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.8","upperLimit":"27.5","value":"23.0"},{"groupId":"OG001","lowerLimit":"11.1","upperLimit":"18.5","value":"14.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"384"}],"units":"Participants"}],"description":"Distant failure rates were estimated by the cumulative incidence method, with failure defined as the first occurrence of distant failure. Patients alive without distant metastases at time of analysis were censored. Death without distant metastasis was treated as a competing risk. Four-year follow-up was required of all patients, but twelve-year rates were reported. Patients are followed until death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy (64.8 Gy) + placebo (daily 2 years)","id":"OG000","title":"Placebo"},{"description":"Radiation therapy (64.8 Gy) + bicalutamide (150 mg daily 2 years)","id":"OG001","title":"Bicalutamide"}],"paramType":"NUMBER","populationDescription":"Eligible patients who did not withdraw consent.","reportingStatus":"POSTED","timeFrame":"From date of randomization to 12 years.","title":"Distant Failure (12-year Rates Reported)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}